Mumbai, June 5 -- The product is bioequivalent and therapeutically equivalent to the reference listed drug, Xeljanz Tablets, of PF Prism C.V. It will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company, and is scheduled for immediate launch.

According to IQVIA MAT data for the 12 months ended April 2026, the US market for Tofacitinib tablets is estimated at approximately $494 million. Following this approval, Aurobindo Pharma has a total of 586 ANDA approvals from the USFDA, comprising 561 final approvals and 25 tentative approvals.

Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to se...